Polypharmacology: challenges and opportunities in drug discovery.

At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.

[1]  M. Kuhar,et al.  The binding of vinblastine to tubulin and to particulate fractions of mammalian brain. , 1974, Cancer research.

[2]  P. Verdouw,et al.  Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. , 1985, Biochemical pharmacology.

[3]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[4]  W. Silverman The schizophrenic career of a "monster drug". , 2002, Pediatrics.

[5]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[6]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[7]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[8]  B. Cronstein,et al.  Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.

[9]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[10]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[11]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[12]  R. Krauss,et al.  When good drugs go bad , 2007, Nature.

[13]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[14]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[15]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[16]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[17]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[18]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[19]  Tudor I. Oprea,et al.  Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..

[20]  Deok-Sun Lee,et al.  A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism , 2009, PLoS Comput. Biol..

[21]  David A. Fidock,et al.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.

[22]  J. Mestres,et al.  Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.

[23]  Shuxing Zhang,et al.  Mapping drug-target interaction networks , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[24]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[25]  G. Degliesposti,et al.  Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening , 2009, Chemical biology & drug design.

[26]  Giulio Rastelli,et al.  Structure‐Based and in silico Design of Hsp90 Inhibitors , 2009, ChemMedChem.

[27]  Mathias Wawer,et al.  Navigating structure-activity landscapes. , 2009, Drug discovery today.

[28]  Andrew J. S. Knox,et al.  Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. , 2009, Journal of medicinal chemistry.

[29]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[30]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[31]  Jeffrey A. Cohen,et al.  Combination therapy in multiple sclerosis , 2010, The Lancet Neurology.

[32]  Jürgen Bajorath,et al.  Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..

[33]  D. Altieri Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. , 2010, Future oncology.

[34]  Michael J. Keiser,et al.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.

[35]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[36]  J. Wright,et al.  Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy , 2010, Clinical Cancer Research.

[37]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[38]  Pablo C. Echeverría,et al.  An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.

[39]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[40]  Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials. , 2011, Clinical lung cancer.

[41]  Anne Mai Wassermann,et al.  Design of Multitarget Activity Landscapes That Capture Hierarchical Activity Cliff Distributions , 2011, J. Chem. Inf. Model..

[42]  Alison Stopeck,et al.  HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.

[43]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[44]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..

[45]  Irene Bolea,et al.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.

[46]  Maurizio Recanatini,et al.  The role of fragment-based and computational methods in polypharmacology. , 2012, Drug discovery today.

[47]  Jin-jian Lu,et al.  Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.

[48]  J. Roder,et al.  Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.

[49]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[50]  Xiangyi Lu,et al.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. , 2012, Biochemical pharmacology.

[51]  J. Richard Morphy,et al.  Designing multi-target drugs , 2012 .

[52]  Wolfgang Guba,et al.  Can we discover pharmacological promiscuity early in the drug discovery process? , 2012, Drug discovery today.

[53]  Gergely Zahoránszky-Köhalmi,et al.  Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..

[54]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[55]  L. Meijer,et al.  Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. , 2012, Journal of medicinal chemistry.

[56]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[57]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[58]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[59]  G. Rastelli,et al.  αC helix displacement as a general approach for allosteric modulation of protein kinases. , 2013, Drug discovery today.

[60]  José Marco-Contelles,et al.  Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.

[61]  Jürgen Bajorath,et al.  High-resolution view of compound promiscuity , 2013, F1000Research.

[62]  J. Roder,et al.  Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice , 2013, Neuropharmacology.

[63]  P. Bork,et al.  Systematic identification of proteins that elicit drug side effects , 2013, Molecular systems biology.

[64]  Irina G. Tikhonova,et al.  Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles , 2013, J. Chem. Inf. Model..

[65]  Jürgen Bajorath,et al.  Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families , 2013, J. Chem. Inf. Model..

[66]  Emidio Camaioni,et al.  PARP inhibitors: polypharmacology versus selective inhibition , 2013, The FEBS journal.

[67]  Jürgen Bajorath,et al.  Activity profile relationships between structurally similar promiscuous compounds. , 2013, European journal of medicinal chemistry.

[68]  C. Ballard,et al.  Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease , 2013, Pharmaceuticals.

[69]  J. Mestres,et al.  On the origins of drug polypharmacology , 2013 .

[70]  R. Geney,et al.  Type II kinase inhibitors: an opportunity in cancer for rational design. , 2013, Anti-cancer agents in medicinal chemistry.

[71]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[72]  Jürgen Bajorath,et al.  Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families , 2013 .

[73]  Mårten Fryknäs,et al.  Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[74]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[75]  G. Fontanini,et al.  Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. , 2013, The Journal of clinical endocrinology and metabolism.

[76]  R. McKenna,et al.  Insights towards sulfonamide drug specificity in α-carbonic anhydrases. , 2013, Bioorganic & medicinal chemistry.

[77]  Giulio Rastelli Emerging Topics in Structure-Based Virtual Screening , 2013, Pharmaceutical Research.

[78]  L. Rubinstein,et al.  Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995–2011 , 2013, Melanoma research.

[79]  Yuhong Du,et al.  Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. , 2013, Biochemical pharmacology.

[80]  P. Sadler,et al.  Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis , 2013, ACS chemical biology.

[81]  Ruben Abagyan,et al.  The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.

[82]  J. Peters Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[83]  Giulio Rastelli,et al.  Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure , 2013, J. Chem. Inf. Model..

[84]  Jürgen Bajorath,et al.  New frontiers in kinases: second generation inhibitors. , 2014, Journal of medicinal chemistry.

[85]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[86]  N. Curtin PARP inhibitors for anticancer therapy. , 2014, Biochemical Society transactions.